Disclaimer РThe EAC/RNAS Guidelines represent the views of the EAC and RNAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC and RNAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC/RNAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC/RNAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC/RNAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC/RNAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Members of the Working Group confirmed the lack of financial support / conflict of interest. In the event of a conflict of interest being reported, the member (s) of the Working Group was (were) excluded from the discussion of sections related to the area of conflict of interest.

The purpose of the work. Learning the features of spreading of hypertriglyceridemia among elderly population and its connection with hypercholesterolemia (HXS).

Materials and methods. At the same time a survey questionnaire (SF-36 uestionnaire) was conducted and finger-prick blood was tested. The blood test trial was carried out with the help of «Accutrend Plus» portable device. The concentration of triglycerides and cholesterol appeared on the screen within 1-2 minutes with the help of the test system.

Results. TG was found in 33,7±1,1% of the population, it was 1,8±2,2 mmol/l in 24,5±1,0%, correspondingly 2,3±5.6 mmol/l (Р<0,005) in 7,7±0,6%, more than 5,7 mmol/l (Р<0,001) in 1,5±0,7%. The random frequency of HTG is rising according to population age increase (q=+0,88±0,09). HTG was 37.0±1,6% among men, and 31,2±1,4% among women (P<0,01). In 25,6±1,0% of cases HTG was observed with HCS, but in 3,1±0,4% of cases it was observed independently.

Consequences. Research is important to clarify the role of HTG in the development of cardiovascular diseases in the background of a fairly wide distribution of HTG among the population.

Aim: to analyze an adherence to treatment, factors affecting it, and the quality of life of patients with cardiovascular diseases at the outpatient stage of medical care.

Material and methods. The population of the study was 225 people. The Moriski-green compliance scale was used to analyze patients’ adherence to treatment, and the EuroQol EQ-5D-5L international questionnaire was used to assess the quality of life of patients. Statistical data processing was performed using the program STATISTICA 10.0.

Results. The percentage of committed to treating patients who sought outpatient care was 59%. The main reason for poor adherence was forgetfulness – 25,27 %. It is patient’s opinion, in 73.8% of cases, communication with a doctor plays an important role in improving their compliance. The total index of quality of life (QOL) of patients with cardiovascular diseases (CVD) was 0.712 ± 0.165. In estimating the relationship between quality of life and adherence to treatment, a positive correlation was found: the more compliant the patient, the higher their quality of life, and vice versa (r=0.2, p=0.013). The relationship between high adherence to treatment and quality of life was confirmed in the group of men (p=0.01), while the statistical significance of differences was not achieved in women (p=0.2). In examining the aspect of a disease of chronic heart failure (CHF), the worsening of NYHA functional class (from I to II) was accompanied by a sharp decrease in self-esteem of health for both sexes (p=0.01).

Conclusion. Almost every second patient is against of the rules of the medication regimen. Better adherence to treatment can be facilitated by more careful attention from the attending physician with a detailed explanation of the causes and the aspect of the disease, treatment methods, as well as ways to self-control the symptoms of the disease. The degree of treatment adherence is correlated with the level of quality of life on the EQ-5D-5L scale, mainly in the male population.

Aim: to evaluate the efficacy and safety of the use of evolocumab in patients with familial hypercholesterolemia (FH).

Materials and methods: Fifteen patients with a definite FH were treated with PCSK9 inhibitors, in 11 patients with a history of CAD. Eight patients (53.3%) received evolocumab (Repata) subcutaneously 140 mg once every 2 weeks, their average age was 51.4±2.3 years, 6 men. Lipid spectrum, ALT, AST, creatinine, glucose, Lp (a) were evaluated after 3, 6, 12 and 18 months, the ECG and the clinical picture were monitored. Evolocumab was prescribed in connection with the failure to achieve the target LDL. Before the start of therapy, 7 patients received statins, 5 statins with ezetemib, 1 patient did not receive lipid-lowering therapy due to intolerance. The target LDL levels were considered: for very high risk patients less than 1.4 mmol/L, high risk – less than 1.8 mmol/L. Statistical processing of the material was performed using STATISTICA10.0.

Results: On the background of evolocumab therapy, the average level of LDL after 3 months of therapy decreased by 56.4% (from 3.9±0.3 to 1.71±0.2 mmol/L), the effect persisted after a year. All patients did not stop the therapy; there were no side effects, including local ones. Target LDL was achieved in 62.5% of patients, the average LDL level after 3 months of therapy decreased by 56.4% in patients from the initial, including the case of monotherapy with evolocumab. The Lp (a) level during therapy decreased by 30%.

Conclusions: Evolocumab allows to increase the achievement of the target LDL level on 40% in FH patients; target LDL level was achieved in 62.5%. LDL decreased after 3 months by 56.4%, remaining stable with prolonged therapy. The decrease in Lp(a) reached 30%. Evolocumab therapy was characterized by high adherence and the absence of side effects.

Introduction. Due to the growing prevalence of arterial hypertension (AH) among the adult population of industrialized countries, the issues of prevention and treatment of this disease are under the close attention of researchers and are among the most pressing problems of modern cardiology.

Material and methods. The survey of 110 employees (84 women and 26 men) of one of the scientific libraries of Baku city was conducted with the help of a set of standard methods of epidemiological research in cardiology.

Results of the research. The presence of AH was found in 26.4% of persons in the institution under study. Moreover, 15.5% of them were patients with AH, the remaining 10.9% were patients who did not know about their disease. In order to determine the possible risk of new cases of AH in this institution, a comparative analysis of the frequency of occurrence of the main risk factors (RF) of cardiovascular disease (CVD) among the surveyed staff with the presence and absence of AH was conducted. Although all patients without AH were younger than 40 years of age, the incidence of major RF of CVD was noted, in some cases close to that of patients with AH.

Conclusion. The received data testify to the fact that the introduction of preventive measures aimed at the correction of the RF of CVD taking into account the specific conditions and specifics of work in the institution under study will significantly reduce the possibility of new cases of AH among the investigated category of patients.

The pandemic of a new coronavirus infection – COVID-19 («Coronavirus disease 2019») has changed the routine management of patients with pulmonary arterial hypertension (PAH). Like patients with other chronic cardiovascular diseases, PAH patients are not at higher risk of a new coronavirus infection. However, in the current epidemiological situation, the problems of managing high-risk groups are sharply indicated, in which the severe course of COVID-19 with a higher lethality is more often noted. Undoubtedly, рatients with different forms of pulmonary hypertension belong to the high-risk group, considering both the presence of severe lifethreatening cardiovascular pathology and background pathology in cases of the associated forms of the disease.

At the same time, the first foreign experience indicates a rather low incidence and relatively favorable course of COVID-19 in PAH, which allows to formulate a number of hypotheses that will be confirmed or rejected in the near future. The unique problems of managing patients with PAH are those associated with changes in generally accepted standards of medical care and patient routing, which is especially important for patients receiving PAH-specific drugs. The problems of a complex assessment of the risk of possible infection in the event of hospitalization or an outpatient visit of patients on the one hand, and on the other, the risk of PAH progression with a delay in starting treatment, are a dilemma that requires an individual solution. Based on an analysis of current data, this review summarizes the main approaches to managing patients with PAH in the current epidemiological situation.